.jetcityimage/iStock Content via Getty Images Morgan Stanley has decided on Eli Lilly (NYSE: LLY) as its top biopharma choice for 2025 and also ranked an additional nine titles in the space as obese. The investment banking company mentioned in a note that it continues to think “diabesity is set to end up being.